#National Institute of Allergy and Infectious Diseases

Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

A machine learning algorithm designed small sets of proteins that boasted the greatest potential to elicit a broad-based immune response.

Global research teams from three U.S. universities explore this HIV-tuberculosis link, thanks to a $6.2 million grant.

Broad details emerge, such as targeting the HIV hot spots that, when combined, account for 50 percent of new HIV cases.

National Institutes of Health (NIH) officials discuss scientific evidence and principles underlying the U=U concept.

The new federal initiative will work with existing research programs in eight cities.

Periodic infusions of such antibodies may eventually become a new way of treating the virus.

The iconic AIDS activist sounded off in a STAT interview—and shared how he’s spending his declining years.

Promising news on the prevention front

It’s the NIH’s first large-scale clinical trial on the subject. Plus: Meet organ transplant advocate Mo Murray [VIDEO].

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

A statement from the National Institutes of Health on World AIDS Day 2017.

The study of a vaccine that is designed to prevent multiple strains of the virus will include 2,600 women in sub-Saharan Africa.